Clinical Trials Browser

Phase 1/2 × INDUSTRY × Valganciclovir × Clear all

NCT03397706 2025-03-20

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Phase 1/2 Completed

64 enrolled 31 charts

Lymphoproliferative Disorders